News
NXTC
8.23
-2.26%
-0.19
Weekly Report: what happened at NXTC last week (0831-0904)?
Weekly Report · 2d ago
NextCure Ends Beltsville Lease to Cut Operating Costs
TipRanks · 5d ago
Weekly Report: what happened at NXTC last week (0824-0828)?
Weekly Report · 08/31 10:16
Weekly Report: what happened at NXTC last week (0817-0821)?
Weekly Report · 08/24 10:17
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 08/18 17:05
Weekly Report: what happened at NXTC last week (0810-0814)?
Weekly Report · 08/17 10:17
Major Former Stakeholder Makes a Significant Move in NextCure Stock
TipRanks · 08/13 02:13
Analysts Offer Insights on Healthcare Companies: NextCure (NXTC) and CalciMedica (CALC)
TipRanks · 08/12 17:00
RTW Bio's Avere To Merge With NextCure
NASDAQ · 08/12 06:26
NextCure Reports Q2 Loss As Proposed Avere Merger Reshapes Strategic Direction
NASDAQ · 08/10 13:17
Weekly Report: what happened at NXTC last week (0803-0807)?
Weekly Report · 08/10 10:13
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/07 21:05
NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate
Benzinga · 08/06 21:47
NextCure GAAP EPS of -$2.80 misses by $0.88
Seeking Alpha · 08/06 21:35
Press Release: NextCure Provides Business Update -3-
Dow Jones · 08/06 20:01
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 08/04 17:05
Major Investor Makes Bold Move on NextCure Shares
TipRanks · 08/04 02:02
Weekly Report: what happened at NXTC last week (0727-0731)?
Weekly Report · 08/03 10:12
Major Investor Makes Bold Move on NextCure Shares
TipRanks · 07/30 02:03
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 07/28 21:06
More
Webull provides a variety of real-time NXTC stock news. You can receive the latest news about Nextcure through multiple platforms. This information may help you make smarter investment decisions.
About NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.